Degradar KRAS logra una marcada regresión del cáncer de pulmón en modelos de estudio

KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas. For decades, it was considered undruggable, until the recent approval of the first inhibitors against specific KRAS mutants. However, these treatments often lose efficacy over time due to the emergence of resistance. Now, this new study explores a different pharmacological strategy based on inducing tumour cells to degrade mutant KRAS themselves.

TanyaY

Stats

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.